Synthetic analog · 39 amino acids · 4,316 Da

Glepaglutide studies and research data

PepBank has 13 glepaglutide studies with results. All of them gave glepaglutide, with 86 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.

Searches 86 results and 28 papers. Newer studies from Europe PMC

Results in people

83% of 86 results

Results in animals

17% of 86 results

Results in lab cells

0% of 86 results

From computer models

0% of 86 results

The molecule

Glepaglutide identity

Identifiers, parent molecule, targets and development stage, from curated data.

Glepaglutide is a 39-residue GLP-2 analog with a C-terminal lysine extension. It differs from apraglutide and teduglutide. Its development concerns reduced dependence on parenteral support.

Kind: Synthetic analog · 39 residues
Identifiers: ChEMBLCHEMBL4297761 (opens in a new tab)PubChem CID146170995 (opens in a new tab)UNII4M3C1913N6 (opens in a new tab)DrugBankDB14794 (opens in a new tab)CAS914009-86-2KEGGD11337 (opens in a new tab)IUPHAR10885 (opens in a new tab)
Parent: Analog of Human GLP-2 · residues 146-178UniProt P01275 places mature human GLP-2 at precursor residues 146-178. Substitution positions use mature GLP-2 numbering. Glepaglutide adds six C-terminal lysines and a terminal amide. FDA SRS and the medicinal chemistry paper establish these changes.
Development: Phase 3Zealand PharmaPhase 3 development continues. The sponsor reports EASE-5 recruitment from January 2026 and an EASE-6 extension. EMA reports a positive CHMP opinion. These facts do not establish marketing approval. Source (opens in a new tab)

Targets

Molecular targets with action and evidence source
Target	Action	Evidence
GLP2RGLP2RO95838 (opens in a new tab)	Agonist	Primary receptor pharmacology and KEGG target annotation.Source (opens in a new tab)
GLP1RGLP1RP43220 (opens in a new tab)	Agonist	The primary study identifies glepaglutide as a GLP2R/GLP1R dual agonist.Source (opens in a new tab)

Sequence and structure

Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.

Sequence

39 amino acids · 1 modification

H-

HGEGTFSSEL

ATILDALAAR

DFIAWLIATK

ITDKKKKKK

Parent: Human GLP-2

No sequence is listed for the parent, so no alignment is shown.UniProt P01275 places mature human GLP-2 at precursor residues 146-178. Substitution positions use mature GLP-2 numbering. Glepaglutide adds six C-terminal lysines and a terminal amide. FDA SRS and the medicinal chemistry paper establish these changes.

Properties

From identity sources

Formula: C₁₉₇H₃₂₅N₅₃O₅₅
Molecular weight: 4,316 g/mol
Monoisotopic mass: 4,313.4264 Da

PubChem CID 146170995(opens in a new tab)retrieved 2026-10-27
FDA SRS(opens in a new tab)retrieved 2026-10-27
IUPHAR/BPS(opens in a new tab)retrieved 2026-10-27
primary medicinal chemistry(opens in a new tab)retrieved 2026-10-27

Calculated from the sequence

pKa set

Average mass: 4,316.07 Da; Sum of ExPASy residue masses + water + C-amide · ExPASy Compute pI/Mw; FindMod
Monoisotopic mass: 4,313.4263 Da; Sum of ExPASy residue masses + water + C-amide · ExPASy FindMod
Isoelectric point (pI): 10.67; pH of zero net charge, EMBOSS pKa set · EMBOSS iep, Epk.dat
Net charge at pH 7.4: 4.05; Henderson-Hasselbalch, EMBOSS pKa set · EMBOSS iep, Epk.dat
GRAVY (hydropathy): −0.231; Mean Kyte-Doolittle hydropathy · Kyte and Doolittle 1982; Negative: hydrophilic on average.
Extinction coefficient, 280 nm (Cys reduced): 5,500 M⁻¹ cm⁻¹; 5500 x Trp + 1490 x Tyr · Pace et al. 1995 (ExPASy ProtParam)
Instability index: 17.83; Dipeptide instability weights (DIWV) · Guruprasad et al. 1990; 40 or below: classed as stable (ExPASy).
Aliphatic index: 95.4; Mole % A + 2.9 V + 3.9 (I + L) · Ikai 1980
Boman index: 1.41 kcal/mol; Mean solubility value (negated) · Boman 2003; 2.48 or below: lower protein-binding potential (Boman).
Hydrophobic moment (μH): 0.401; Eisenberg scale, 100° per residue, best 11-residue window · Eisenberg et al. 1982, 1984
pI with each pKa set: EMBOSS 10.67Bjellqvist (ExPASy) 9.87IPC peptide 10.42IPC protein 9.06

Defined and validated for proteins; use with care for short peptides.
Assumes an ideal alpha helix. Many short peptides are not helical.

@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses

Net charge by pH

pI 10.67 · Net charge at pH 7.4: 4.05

Point or use arrow keys

Henderson-Hasselbalch, EMBOSS pKa set, C-amide. Calculated, not measured.

Show as table

pH	Net charge
0	10.00
1	9.99
2	9.95
3	9.52
4	7.44
5	5.41
6	4.81
7	4.22
8	3.82
9	3.18
10	2.08
11	−1.32
12	−3.82
13	−4.72
14	−4.96

Composition

Hydrophobic36% (14)A I L
Aromatic8% (3)F W
Positive23% (9)H K R
Negative13% (5)D E
Polar15% (6)S T
Special5% (2)G

39 residues. Each residue counts in one class; F and W count as aromatic.

A Ala6 · 15%

I Ile4 · 10%

L Leu4 · 10%

M Met0 · 0%

V Val0 · 0%

F Phe2 · 5%

W Trp1 · 3%

Y Tyr0 · 0%

H His1 · 3%

K Lys7 · 18%

R Arg1 · 3%

D Asp3 · 8%

E Glu2 · 5%

N Asn0 · 0%

Q Gln0 · 0%

S Ser2 · 5%

T Thr4 · 10%

C Cys0 · 0%

G Gly2 · 5%

P Pro0 · 0%

3D structure

PredictedAlphaFold DB · P01275

Loads the 3D viewer (3Dmol.js, about 150 KB) and the model file from AlphaFold DB (EMBL-EBI).

2D structure

Glepaglutide has 39 residues. A full-atom drawing is hard to read at this size; the sequence view is the reference.

SMILES fromPubChem CID 146170995(opens in a new tab)

CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC5=CNC=N5)N

Helical wheel

An ideal alpha-helix projection. It shows where the hydrophobic residues fall if the peptide folds as a helix. It does not show that it does.

μH, residues shown: 0.079
μH, best 11-residue window: 0.401
Arrow direction: 186°
Residues: 39 · 3 rings of 18

HydrophilicHydrophobic

Eisenberg consensus (normalized) scale · + K, R · − D, E

Assumes an ideal α-helix: 100° per residue, 3.6 residues per turn. The arrow is the mean hydrophobic moment (Eisenberg et al. 1984) and points at the hydrophobic face.

Show as table

Position	Residue	Angle	Eisenberg consensus (normalized)
1	H	0°	-0.40
2	G	100°	0.48
3	E	200°	-0.74
4	G	300°	0.48
5	T	40°	-0.05
6	F	140°	1.19
7	S	240°	-0.18
8	S	340°	-0.18
9	E	80°	-0.74
10	L	180°	1.06
11	A	280°	0.62
12	T	20°	-0.05
13	I	120°	1.38
14	L	220°	1.06
15	D	320°	-0.90
16	A	60°	0.62
17	L	160°	1.06
18	A	260°	0.62
19	A	0°	0.62
20	R	100°	-2.53
21	D	200°	-0.90
22	F	300°	1.19
23	I	40°	1.38
24	A	140°	0.62
25	W	240°	0.81
26	L	340°	1.06
27	I	80°	1.38
28	A	180°	0.62
29	T	280°	-0.05
30	K	20°	-1.50
31	I	120°	1.38
32	T	220°	-0.05
33	D	320°	-0.90
34	K	60°	-1.50
35	K	160°	-1.50
36	K	260°	-1.50
37	K	0°	-1.50
38	K	100°	-1.50
39	K	200°	-1.50

Results by area

Glepaglutide results by year and outcome

Counts are exact and come from studies that gave the peptide.

Studies by year

13 of 28 studies have results (46%), published 2019 to 2026. Top row: every study. Bottom row: studies with results about Glepaglutide, by class. The rows use different scales.

Studies
Human
Animal
Lab
Computer model
Natural levels, tool or combination only

Studies28 in all, 2019 to 2026

Studies with results13 in all, 2019 to 2026

Retracted studies are left out. A study with results in two classes counts in both.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

What the studies measured

People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.

Glepaglutide studies on stomach and gut

34 results · people 20 · animals 14 · lab 0

Top 5 of 34 results

In adults with short bowel syndrome, glepaglutide reduced faecal output from baseline.The lancet. Gastroenterology & hepatology, 2019
In patients with short bowel syndrome, glepaglutide increased time to 10% gastric emptying of solids from baseline.JPEN. Journal of parenteral and enteral nutrition, 2020
In patients with short bowel syndrome, intestinal bacterial amounts showed no major changes after glepaglutide treatment.Clinical nutrition ESPEN, 2026
In rats with intestinal inflammation, glepaglutide co- and post-treatment significantly reduced inflammation severity.BMC gastroenterology, 2023
In patients with short bowel syndrome, glepaglutide increased plasma citrulline from baseline.JPEN. Journal of parenteral and enteral nutrition, 2023

Glepaglutide studies on side effects

19 results · people 19 · animals 0 · lab 0

Top 5 of 19 results

In adults with short bowel syndrome, treatment-related peripheral oedema occurred in 56% of patients receiving glepaglutide.The lancet. Gastroenterology & hepatology, 2019
In adults with short bowel syndrome, treatment-related nausea occurred in 44% of patients receiving glepaglutide.The lancet. Gastroenterology & hepatology, 2019
In adults with short bowel syndrome receiving glepaglutide, related or possibly related serious adverse events included catheter-related sepsis.The lancet. Gastroenterology & hepatology, 2019
In adults with short bowel syndrome, treatment-related stoma complications occurred in 72% of patients receiving glepaglutide.The lancet. Gastroenterology & hepatology, 2019
In adults with short bowel syndrome, treatment-related polyuria occurred in 33% of patients receiving glepaglutide.The lancet. Gastroenterology & hepatology, 2019

Glepaglutide studies on liver

12 results · people 12 · animals 0 · lab 0

Top 3 of 12 results

In patients with short bowel syndrome, transient elastography values increased from baseline during glepaglutide treatment.EBioMedicine, 2019
In patients with short bowel syndrome, glepaglutide increased postprandial FGF19 response from baseline.JPEN. Journal of parenteral and enteral nutrition, 2022
In patients with short bowel syndrome, indocyanine green elimination increased from baseline during glepaglutide treatment.EBioMedicine, 2019

Glepaglutide studies on survival and serious illness

7 results · people 7 · animals 0 · lab 0

Top 4 of 7 results

In SBS-CIF patients without sodium depletion, glepaglutide reduced parenteral support more than placebo.Clinical nutrition ESPEN, 2026
In adults with short bowel syndrome receiving glepaglutide, no patients died during the trial.The lancet. Gastroenterology & hepatology, 2019
In patients with short bowel syndrome, parenteral support volume decreased from baseline with glepaglutide.Clinical nutrition ESPEN, 2025
In nondepleted SBS-CIF patients, clinical response was numerically more likely with glepaglutide than placebo, but the difference was not significant.Clinical nutrition ESPEN, 2026

Glepaglutide studies on blood levels and clearance

5 results · people 5 · animals 0 · lab 0

Top 3 of 5 results

In healthy subjects, mean effective glepaglutide half-life was 124 h with 5 mg dosing.Clinical drug investigation, 2022
In healthy subjects, mean effective glepaglutide half-life was 88 h with 10 mg dosing.Clinical drug investigation, 2022
In healthy subjects, comparison with intravenous dosing indicated that slow metabolite release mainly determined glepaglutide levels after subcutaneous dosing.Clinical drug investigation, 2022

Glepaglutide studies on weight and appetite

3 results · people 3 · animals 0 · lab 0

3 results

In adults with short bowel syndrome, treatment-related decreased appetite occurred in 22% of patients receiving glepaglutide.The lancet. Gastroenterology & hepatology, 2019
In patients with short bowel syndrome, body composition remained stable during glepaglutide treatment.Clinical nutrition ESPEN, 2025
In patients with short bowel syndrome, body weight remained stable during glepaglutide treatment.Clinical nutrition ESPEN, 2025

Glepaglutide studies on daily life and fitness

2 results · people 2 · animals 0 · lab 0

2 results

In patients with SBS-IF, 73% receiving glepaglutide reported better quality of life versus 25% receiving placebo.Nutrition in clinical practice, 2026
Among patients reporting a status change, 94% receiving glepaglutide found it meaningful versus 67% receiving placebo.Nutrition in clinical practice, 2026

Glepaglutide studies on receptors and cell signals

2 results · people 2 · animals 0 · lab 0

2 results

In patients with short bowel syndrome, glepaglutide did not significantly change intestinal gene expressions from baseline.JPEN. Journal of parenteral and enteral nutrition, 2023
In patients with short bowel syndrome, FXR gene expression did not change from baseline in any glepaglutide dose group.JPEN. Journal of parenteral and enteral nutrition, 2022

Glepaglutide studies on heart and blood vessels

1 result · people 1 · animals 0 · lab 0

1 result

In patients with short bowel syndrome, glepaglutide did not significantly change intestinal perfusion from baseline.JPEN. Journal of parenteral and enteral nutrition, 2023

Glepaglutide studies on immune system and inflammation

1 result · people 0 · animals 1 · lab 0

1 result

In rats with intestinal inflammation, glepaglutide decreased α-1-acid glycoprotein and/or myeloperoxidase concentrations.BMC gastroenterology, 2023

Trials and papers

Glepaglutide trials

Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.

StatusPhase

11 trials match. Highest phase first. Data from ClinicalTrials.gov.

Trials on this page (11 of 11)

11 trials · 2 ongoing · 9 completed · 2 with posted results

Completed
Ongoing
Not yet recruiting
Stopped
Estimated dates (est.)
Results posted

20102015202020252030

Ph 1
Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending Dose
NCT00868660
Jan 2009 to Feb 2010
Ph 2
glepaglutide
NCT02690025
Feb 2016 to May 2017
Ph 1
Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects
NCT03279302
4 Sept 2017 to 18 Dec 2017
Ph 3
EASE SBS 1
NCT03690206
4 Oct 2018 to 26 Jul 2022
Ph 3
EASE SBS 2
NCT03905707
7 May 2019 to 30 Apr 2026
Ph 1
Pharmacokinetic Profile of Glepaglutide After a Single Injection in Subjects With Varying Degrees of Renal Function
NCT04178447
10 Dec 2019 to 14 Jul 2020
Ph 1
A Bridging Trial to Compare the PK Profile When Glepaglutide is Administered Via Vial/Syringe Versus Autoinjector.
NCT04318743
4 Mar 2020 to 10 Jun 2021
Ph 3
EASE SBS 3
NCT04881825
16 Jun 2021 to 30 Apr 2026
Ph 3
EASE SBS 4
NCT04991311
10 Aug 2021 to 5 Sept 2023
Ph 3
EASE SBS 6
NCT07228403
11 Dec 2025 to est. 31 Dec 2028

11 trials · 2 ongoing · 9 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase 3NCT07197944

Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

Zealand Pharman = 9011 Feb 2026 to est. 28 Feb 2032

Short Bowel Syndrome

Trial page ClinicalTrials.govUpdated 29 Sept 2026

CompletedPhase 3NCT03905707

Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS

Zealand Pharman = 1507 May 2019 to 30 Apr 2026

Short Bowel Syndrome

Trial page ClinicalTrials.govUpdated 8 Sept 2026

CompletedPhase 3NCT04881825

Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial

Zealand Pharman = 8416 Jun 2021 to 30 Apr 2026

Short Bowel Syndrome

Trial page ClinicalTrials.govUpdated 8 Sept 2026

Active, not recruitingPhase 3NCT07228403

Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome

Zealand Pharman = 2811 Dec 2025 to est. 31 Dec 2028

Short Bowel Syndrome (SBS)

Trial page ClinicalTrials.govUpdated 30 Jul 2026

CompletedPhase 3Results postedNCT03690206

Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)

Zealand Pharman = 1064 Oct 2018 to 26 Jul 2022

Short Bowel Syndrome

Trial page ClinicalTrials.govUpdated 17 Jul 2025

CompletedPhase 3Results postedNCT04991311

The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome

Zealand Pharman = 1210 Aug 2021 to 5 Sept 2023

Short Bowel Syndrome

Trial page ClinicalTrials.govUpdated 22 Nov 2024

CompletedPhase 2NCT02690025

A Phase 2 Trial Testing ZP1848 in Patients With SBS

Zealand Pharman = 18Feb 2016 to May 2017

Short Bowel Syndrome

Trial page ClinicalTrials.govUpdated 21 Jun 2017

CompletedPhase 1NCT04318743

A Bridging Trial to Compare the PK Profile When Glepaglutide is Administered Via Vial/Syringe Versus Autoinjector.

Zealand Pharman = 854 Mar 2020 to 10 Jun 2021

Healthy

Trial page ClinicalTrials.govUpdated 14 Jul 2021

CompletedPhase 1NCT04178447

Pharmacokinetic Profile of Glepaglutide After a Single Injection in Subjects With Varying Degrees of Renal Function

Zealand Pharman = 1610 Dec 2019 to 14 Jul 2020

Renal Impairment

Trial page ClinicalTrials.govUpdated 18 Nov 2020

CompletedPhase 1NCT03279302

Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects

Zealand Pharman = 754 Sept 2017 to 18 Dec 2017

Healthy Subjects

Trial page ClinicalTrials.govUpdated 22 Dec 2017

CompletedPhase 1NCT00868660

Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending Dose

Zealand Pharman = 66Jan 2009 to Feb 2010

Inflammatory Bowel Disease

Trial page ClinicalTrials.govUpdated 2 Nov 2010

Papers

Studies on this peptide. Some have results. The others have none yet.

Sort

Design

28 studies match. Retracted studies are left out.

Showing 22 of 28 studiesquery qry_6213203cb8e4ef1ac3c2ad9a

Studies with results

13 studies in all, 12 on this page

Randomized controlled trial · 2019

22 results

Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial.

Naimi et al. 2019The lancet. Gastroenterology & hepatologyn = 18cited by 60

PMID 30880176DOI 10.1016/s2468-1253(19)30077-9PUB-30880176

Full text at the publisher22 results where Glepaglutide was given

Publisher page See results (22)

Randomized controlled trial · 2020

6 results

Effect of Glepaglutide, a Long-Acting Glucagon-Like Peptide-2 Analog, on Gastrointestinal Transit Time and Motility in Patients With Short Bowel Syndrome: Findings From a Randomized Trial.

Hvistendahl et al. 2020JPEN. Journal of parenteral and enteral nutritionn = 9cited by 38

PMID 32022286DOI 10.1002/jpen.1767PUB-32022286

Full text at the publisher6 results where Glepaglutide was given

Publisher page See results (6)

Randomized controlled trial · 2019

9 results

Effects of glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, on markers of liver status in patients with short bowel syndrome: findings from a randomised phase 2 trial.

Naimi et al. 2019EBioMedicinen = 18cited by 25

PMID 31326433PMC6710908DOI 10.1016/j.ebiom.2019.07.016PUB-31326433

Free to read · publisher termsCC BY-NC-ND9 results where Glepaglutide was given

Read at source See results (9)

Randomized controlled trial · 2023

7 results

Effects of glepaglutide, a long-acting glucagon-like peptide-2 analog, on intestinal morphology and perfusion in patients with short bowel syndrome: Findings from a randomized phase 2 trial.

Naimi et al. 2023JPEN. Journal of parenteral and enteral nutritioncited by 21

PMID 35511704PMC10084040DOI 10.1002/jpen.2389PUB-35511704

Free to read · publisher termsCC BY-NC-ND7 results where Glepaglutide was given

Read at source See results (7)

Randomized controlled trial · 2022

4 results

Bile acid-farnesoid X receptor-fibroblast growth factor 19 axis in patients with short bowel syndrome: The randomized, glepaglutide phase 2 trial.

Hvistendahl et al. 2022JPEN. Journal of parenteral and enteral nutritioncited by 14

PMID 34287979DOI 10.1002/jpen.2224PUB-34287979

Full text at the publisher4 results where Glepaglutide was given

Publisher page See results (4)

Randomized controlled trial · 2022

7 results

Pharmacokinetics of Glepaglutide, A Long-Acting Glucagon-Like Peptide-2 Analogue: A Study in Healthy Subjects.

Agersnap et al. 2022Clinical drug investigationn = 15cited by 12

PMID 36323988PMC9705454DOI 10.1007/s40261-022-01210-1PUB-36323988

Free to read · publisher termsCC BY-NC7 results where Glepaglutide was given

Read at source See results (7)

Animal study (in vivo) · wistar rats · 2023

5 results

Glepaglutide, a novel glucagon-like peptide-2 agonist, has anti-inflammatory and mucosal regenerative effects in an experimental model of inflammatory bowel disease in rats.

Skarbaliene et al. 2023BMC gastroenterologycited by 11

PMID 36944922PMC10029296DOI 10.1186/s12876-023-02716-4PUB-36944922

CC BY5 results where Glepaglutide was given

Download PDF See results (5)

Animal study (in vivo) · wistar rats and beagle dogs · 2022

6 results

Short- versus long-term, gender and species differences in the intestinotrophic effects of long-acting glucagon-like peptide 2 analog.

Glerup et al. 2022Physiological researchcited by 5

PMID 35344672PMC9150555DOI 10.33549/physiolres.934839PUB-35344672

Rights unknown6 results where Glepaglutide was given

Source link See results (6)

Non-randomized trial · 2025

8 results

Outcomes of glepaglutide on intestinal absorption and parenteral support in patients with short bowel syndrome.

Pinar et al. 2025Clinical nutrition ESPENn = 10cited by 3

PMID 40774623DOI 10.1016/j.clnesp.2025.08.006PUB-40774623

Full text at the publisher8 results where Glepaglutide was given

Publisher page See results (8)

Animal study (in vivo) · 2025

4 results

Glepaglutide-Loaded Foam for the Induction of Mucosal Healing in the Treatment of Inflammatory Bowel Disease.

Zhang et al. 2025Advanced healthcare materialscited by 2

PMID 39905897PMC11912111DOI 10.1002/adhm.202403497PUB-39905897

Free to read · publisher termsCC BY-NC4 results where Glepaglutide was given

Read at source See results (4)

Non-randomized trial · 2026

2 results

Investigation of the stool microbiome of short bowel syndrome patients before and after a 24-week treatment with the glucagon-like peptide 2 analog glepaglutide.

Pinar et al. 2026Clinical nutrition ESPENn = 10

PMID 41759957DOI 10.1016/j.clnesp.2026.102989PUB-41759957

Full text at the publisher2 results where Glepaglutide was given

Publisher page See results (2)

Randomized controlled trial · 2026

2 results

Exploring the disease burden and quality of life in patients with short bowel syndrome with intestinal failure: Insights from exit interviews in the glepaglutide EASE SBS-1 phase 3 trial.

Mercer et al. 2026Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutritionn = 30

PMID 41816796PMC13419254DOI 10.1002/ncp.70109PUB-41816796

CC BY2 results where Glepaglutide was given

Download PDF See results (2)

More studies

11 studies in all, 10 on this page

PubMed tag: Review · 2022

Therapeutic Potential of GLP-2 Analogs in Gastrointestinal Disorders: Current Knowledge, Nutritional Aspects, and Future Perspectives.

Kounatidis et al. 2022Current nutrition reportscited by 22

PMID 35933503DOI 10.1007/s13668-022-00433-0PUB-35933503

Full text at the publisher

Publisher page

PubMed tag: Randomized Controlled Trial, Clinical Trial, Phase III · 2025

Corrected

Glepaglutide, a Long-Acting Glucagon-like Peptide-2 Analogue, Reduces Parenteral Support in Patients With Short Bowel Syndrome: A Phase 3 Randomized Controlled Trial.

Jeppesen et al. 2025Gastroenterologycited by 22

PMID 39708985DOI 10.1053/j.gastro.2024.11.023PUB-39708985

Full text at the publisher

Publisher page Read the notice

PubMed tag: Network Meta-Analysis, Systematic Review · 2024

Efficacy and safety of glucagon-like peptide 2 in patients with short bowel syndrome: a systematic review and network meta-analysis.

Sabra et al. 2024Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tractcited by 13

PMID 38663565DOI 10.1016/j.gassur.2024.04.009PUB-38663565

Full text at the publisher

Publisher page

PubMed tag: review-article, Review · 2022

An updated overview of glucagon-like peptide-2 analog trophic therapy for short bowel syndrome in adults.

Zhu et al. 2022The Journal of international medical researchcited by 12

PMID 35343263PMC8966062DOI 10.1177/03000605221086145PUB-35343263

Free to read · publisher termsCC BY-NC

Read at source

PubMed tag: none · 2023

Corrected

Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment.

Agersnap et al. 2023Clinical pharmacokineticscited by 6

PMID 36811175PMC10085944DOI 10.1007/s40262-023-01215-9PUB-36811175

Free to read · publisher termsCC BY-NC

Read at source Read the notice

PubMed tag: Review · 2024

Intestinal adaptation and rehabilitation in adults with short bowel syndrome.

Pironi et al. 2024Current opinion in clinical nutrition and metabolic carecited by 5

PMID 38963563DOI 10.1097/mco.0000000000001053PUB-38963563

Full text at the publisher

Publisher page

PubMed tag: Meta-Analysis, Systematic Review · 2026

Positive clinical outcomes associated with use of glucagon-like peptide-2 (GLP-2) analogues in patients with intestinal failure: A systematic review and meta-analysis.

Bastas et al. 2026Clinical nutrition ESPENcited by 1

PMID 41344401DOI 10.1016/j.clnesp.2025.11.132PUB-41344401

Full text at the publisher

Publisher page

PubMed tag: review-article, Review · 2025

Glucagon-Like Peptide-2 (GLP-2) Analogues in Patients With Short Bowel Syndrome Dependent on Parenteral Support: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Hyder et al. 2025JGH open : an open access journal of gastroenterology and hepatologycited by 1

PMID 41424579PMC12717787DOI 10.1002/jgh3.70327PUB-41424579

Free to read · publisher termsCC BY-NC

Read at source

PubMed tag: Review · 2026

Glucagon-like peptide agonists and use in short bowel syndrome - what about the side effects?

Gorard et al. 2026Current opinion in gastroenterology

PMID 41866997DOI 10.1097/mog.0000000000001169PUB-41866997

Full text at the publisher

Publisher page

PubMed tag: review-article, Review · 2026

Beyond intestinal failure: Expanding therapeutic frontiers of glucagon-like peptide-2 in gastrointestinal disease.

Attieh et al. 2026World journal of gastrointestinal pharmacology and therapeutics

PMID 42273249PMC13248184DOI 10.4292/wjgpt.v17.i2.118861PUB-42273249

Free to read · publisher termsCC BY-NC

Read at source

No result for Glepaglutide (3 studies on this page, 4 in all)

These studies name Glepaglutide but give no result for it (for example, the results concern another peptide in the study).

PubMed tag: none · 2020

15 results

Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome.

Hargrove et al. 2020The Journal of pharmacology and experimental therapeuticscited by 51

PMID 32075870DOI 10.1124/jpet.119.262238PUB-32075870

Rights unknown15 results

Source link See results (15)

PubMed tag: none · 2023

Differential Responses of the GLP-1 and GLP-2 Receptors to N-Terminal Modification of a Dual Agonist.

Gibadullin et al. 2023Journal of the American Chemical Societycited by 10

PMID 37235770PMC10335629DOI 10.1021/jacs.3c01628PUB-37235770

Rights unknown

Source link

PubMed tag: none · 2025

Creating Glepaglutide, the First Long-Acting GLP-2 Analogue to Enable a Ready-to-Use Injection.

Larsen et al. 2025Journal of medicinal chemistrycited by 2

PMID 39851172DOI 10.1021/acs.jmedchem.4c02361PUB-39851172

Full text at the publisher

Publisher page

Newer studies

PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.

Glepaglutide studies: 13 papers with results

Page 1 of 1

Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial.
Naimi RM · The lancet. Gastroenterology & hepatology · 2019
Randomized controlled trial · 22 results
Effects of glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, on markers of liver status in patients with short bowel syndrome: findings from a randomised phase 2 trial.
Naimi RM · EBioMedicine · 2019
Randomized controlled trial · 9 results
Sodium depletion is associated with the response to glepaglutide in short bowel syndrome with chronic intestinal failure.
Foerster RH · Clinical nutrition ESPEN · 2026
Randomized controlled trial · 4 results
Exploring the disease burden and quality of life in patients with short bowel syndrome with intestinal failure: Insights from exit interviews in the glepaglutide EASE SBS-1 phase 3 trial.
Mercer DF · Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2026
Randomized controlled trial · 2 results
Pharmacokinetics of Glepaglutide, A Long-Acting Glucagon-Like Peptide-2 Analogue: A Study in Healthy Subjects.
Agersnap MA · Clinical drug investigation · 2022
Randomized controlled trial · 7 results
Effect of Glepaglutide, a Long-Acting Glucagon-Like Peptide-2 Analog, on Gastrointestinal Transit Time and Motility in Patients With Short Bowel Syndrome: Findings From a Randomized Trial.
Hvistendahl MK · JPEN. Journal of parenteral and enteral nutrition · 2020
Randomized controlled trial · 6 results
Effects of glepaglutide, a long-acting glucagon-like peptide-2 analog, on intestinal morphology and perfusion in patients with short bowel syndrome: Findings from a randomized phase 2 trial.
Naimi RM · JPEN. Journal of parenteral and enteral nutrition · 2023
Randomized controlled trial · 7 results
Bile acid-farnesoid X receptor-fibroblast growth factor 19 axis in patients with short bowel syndrome: The randomized, glepaglutide phase 2 trial.
Hvistendahl MK · JPEN. Journal of parenteral and enteral nutrition · 2022
Randomized controlled trial · 4 results
Outcomes of glepaglutide on intestinal absorption and parenteral support in patients with short bowel syndrome.
Pinar I · Clinical nutrition ESPEN · 2025
Non-randomized trial · 8 results
Investigation of the stool microbiome of short bowel syndrome patients before and after a 24-week treatment with the glucagon-like peptide 2 analog glepaglutide.
Pinar I · Clinical nutrition ESPEN · 2026
Non-randomized trial · 2 results
Glepaglutide, a novel glucagon-like peptide-2 agonist, has anti-inflammatory and mucosal regenerative effects in an experimental model of inflammatory bowel disease in rats.
Skarbaliene J · BMC gastroenterology · 2023
Animal study (in vivo) · wistar rats · 5 results
Short- versus long-term, gender and species differences in the intestinotrophic effects of long-acting glucagon-like peptide 2 analog.
Glerup P · Physiological research · 2022
Animal study (in vivo) · wistar rats and beagle dogs · 6 results
Glepaglutide-Loaded Foam for the Induction of Mucosal Healing in the Treatment of Inflammatory Bowel Disease.
Zhang W · Advanced healthcare materials · 2025
Animal study (in vivo) · 4 results

Status and safety

Regulatory and safety

Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.

Regulatory status by jurisdiction, with date and source
Jurisdiction	Body	Status	As of	Source
US	FDA	FDA issued a complete response letter on 19 December 2024. The current sponsor page states that FDA has not approved glepaglutide. An openFDA Drugs@FDA ingredient query returned no matching record.	27 Oct 2026	globenewswire.com (opens in a new tab)
EU	EMA	CHMP adopted a positive opinion for Zeydovio on 17 September 2026. The EMA page reports an opinion, not a European Commission marketing authorisation. No national approval was established.	27 Oct 2026	ema.europa.eu (opens in a new tab)
Sport	WADA	Banned in sport (WADA S0) S0 assessment follows the 2026 rule for non-approved pharmacological substances and the sponsor statement of no health-authority approval.	2026 List	wada-ama.org (opens in a new tab)

Safety outcomes

21 safety results for Glepaglutide.

Human evidence· 21

In adults with short bowel syndrome, treatment-related stoma complications occurred in 13 patients (72%) receiving glepaglutide.
Randomized controlled trialn = 18
Patients with treatment-related stoma complications
13 patients
all randomized patients (n=18)
Proportion with treatment-related stoma complications
72%
all randomized patients (n=18)
In adults with short bowel syndrome, treatment-related injection site reactions occurred in 11 patients (61%) receiving glepaglutide.
Randomized controlled trialn = 18
Patients with treatment-related injection site reactions
11 patients
all randomized patients (n=18)
Proportion with treatment-related injection site reactions
61%
all randomized patients (n=18)
In adults with short bowel syndrome, treatment-related peripheral oedema occurred in ten patients (56%) receiving glepaglutide.
Randomized controlled trialn = 18
Patients with treatment-related peripheral oedema
10 patients
all randomized patients (n=18)
Proportion with treatment-related peripheral oedema
56%
all randomized patients (n=18)
In adults with short bowel syndrome, treatment-related nausea occurred in eight patients (44%) receiving glepaglutide.
Randomized controlled trialn = 18
Patients with treatment-related nausea
8 patients
treatment-related, adults with short bowel syndrome (n=18)
Proportion of patients with treatment-related nausea
44%
treatment-related, adults with short bowel syndrome (n=18)
In adults with short bowel syndrome, treatment-related abdominal pain occurred in eight patients (44%) receiving glepaglutide.
Randomized controlled trialn = 18
Patients with treatment-related abdominal pain
8 patients
treatment-related, adults with short bowel syndrome (n=18)
Proportion of patients with treatment-related abdominal pain
44%
treatment-related, adults with short bowel syndrome (n=18)
In adults with short bowel syndrome, treatment-related polyuria occurred in six patients (33%) receiving glepaglutide.
Randomized controlled trialn = 18
Patients with treatment-related polyuria
6 patients
treatment-related, adults with short bowel syndrome (n=18)
Proportion of patients with treatment-related polyuria
33%
treatment-related, adults with short bowel syndrome (n=18)
In adults with short bowel syndrome, treatment-related fatigue occurred in six patients (33%) receiving glepaglutide.
Randomized controlled trialn = 18
Patients with treatment-related fatigue
6 patients
treatment-related, adults with short bowel syndrome (n=18)
Proportion of patients with treatment-related fatigue
33%
treatment-related, adults with short bowel syndrome (n=18)
In adults with short bowel syndrome, treatment-related abdominal distention occurred in five patients (28%) receiving glepaglutide.
Randomized controlled trialn = 18
Patients with treatment-related abdominal distention
5 patients
treatment-related, adults with short bowel syndrome (n=18)
Proportion of patients with treatment-related abdominal distention
28%
treatment-related, adults with short bowel syndrome (n=18)

Doses studied · 19

The doses that these studies used. They are not recommendations.

1 mg dailyHuman
Species
human
Route
subcutaneous
Duration
3 weeks
Design
Randomized controlled trial
10 mg dailyHuman
Species
human
Route
subcutaneous
Duration
3 weeks
Design
Randomized controlled trial
0·1 mg dailyHuman
Species
human
Route
subcutaneous
Duration
3 weeks
Design
Randomized controlled trial
10 mgHuman
Species
human
Route
Not reported
Duration
three weeks
Design
Randomized controlled trial
1 mgHuman
Species
human
Route
Not reported
Duration
three weeks
Design
Randomized controlled trial
10 mg once or twice weeklyHuman
Species
human
Route
Not reported
Duration
24 weeks
Design
Randomized controlled trial · n = 79

Doses studied in the study results, as given in the studies.
Dose as reported	Class	Species	Route	Duration	Design
1 mg daily	Human	human	subcutaneous	3 weeks	Randomized controlled trial
10 mg daily	Human	human	subcutaneous	3 weeks	Randomized controlled trial
0·1 mg daily	Human	human	subcutaneous	3 weeks	Randomized controlled trial
10 mg	Human	human	Not reported	three weeks	Randomized controlled trial
1 mg	Human	human	Not reported	three weeks	Randomized controlled trial
10 mg once or twice weekly	Human	human	Not reported	24 weeks	Randomized controlled trial · n = 79

6 of 19 shown

PepBank is a research reference. Talk to a doctor before you use any peptide.

Data

Data and API

Data version, change history and code for this peptide.

Data version 30856030 Oct 2026

Peptide

Peptide id: PEP-000136
Peptide version: 2
Peptide hash: f0bcc6016a9ffe5e…
Data version: 308560

Latest changes

27 Oct 2026UpdatedData version 287292
27 Oct 2026CreatedData version 256693

For developers

curl -s https://pepbank.io/v1/briefs/glepaglutide

Evidence summary for Glepaglutide: counts by class, key results with sources, notices, data version.

Peptide as JSON Evidence summary as JSON

Outcome group	Human	Animal	Lab	Computer model	Total
Adverse eventsWhole body	Human: 13 results from 3 studies: 13 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	13
Intestinal growth and absorptionGastrointestinal	Human: 12 results from 4 studies: 9 increase, 2 decrease, 1 no significant change. Strongest design: Randomized controlled trial	Animal: 9 results from 2 studies: 6 increase, 1 decrease, 2 not reported. Strongest design: Animal study (in vivo)	No results	No results	21
Liver fat and liver functionLiver	Human: 12 results from 2 studies: 4 increase, 3 decrease, 5 no significant change. Strongest design: Randomized controlled trial	No results	No results	No results	12
Gastrointestinal adverse eventsGastrointestinal	Human: 6 results from 1 study: 6 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	6
Gastrointestinal motilityGastrointestinal	Human: 6 results from 1 study: 4 increase, 2 no significant change. Strongest design: Randomized controlled trial	No results	No results	No results	6
Intensive care and hospital outcomesGastrointestinal	Human: 6 results from 2 studies: 3 decrease, 3 no significant change. Strongest design: Randomized controlled trial	No results	No results	No results	6
PharmacokineticsPharmacology	Human: 5 results from 1 study: 5 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	5
Gut microbiotaGastrointestinal	Human: 2 results from 1 study: 2 no significant change. Strongest design: Non-randomized trial	No results	No results	No results	2
Quality of lifeGastrointestinal	Human: 2 results from 1 study: 2 increase. Strongest design: Randomized controlled trial	No results	No results	No results	2
Receptor activity and mechanismGastrointestinal	Human: 2 results from 2 studies: 2 no significant change. Strongest design: Randomized controlled trial	No results	No results	No results	2
Appetite and food intakeMetabolic and weight	Human: 1 result from 1 study: 1 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	1
Body compositionMetabolic and weight	Human: 1 result from 1 study: 1 no significant change. Strongest design: Non-randomized trial	No results	No results	No results	1

Outcome group	Human	Animal	Lab	Computer model	Total
Adverse eventsWhole body	Human: 13 results from 3 studies: 13 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	13
Intestinal growth and absorptionGastrointestinal	Human: 12 results from 4 studies: 9 increase, 2 decrease, 1 no significant change. Strongest design: Randomized controlled trial	Animal: 9 results from 2 studies: 6 increase, 1 decrease, 2 not reported. Strongest design: Animal study (in vivo)	No results	No results	21
Liver fat and liver functionLiver	Human: 12 results from 2 studies: 4 increase, 3 decrease, 5 no significant change. Strongest design: Randomized controlled trial	No results	No results	No results	12
Gastrointestinal adverse eventsGastrointestinal	Human: 6 results from 1 study: 6 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	6
Gastrointestinal motilityGastrointestinal	Human: 6 results from 1 study: 4 increase, 2 no significant change. Strongest design: Randomized controlled trial	No results	No results	No results	6
Intensive care and hospital outcomesGastrointestinal	Human: 6 results from 2 studies: 3 decrease, 3 no significant change. Strongest design: Randomized controlled trial	No results	No results	No results	6
PharmacokineticsPharmacology	Human: 5 results from 1 study: 5 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	5
Gut microbiotaGastrointestinal	Human: 2 results from 1 study: 2 no significant change. Strongest design: Non-randomized trial	No results	No results	No results	2
Quality of lifeGastrointestinal	Human: 2 results from 1 study: 2 increase. Strongest design: Randomized controlled trial	No results	No results	No results	2
Receptor activity and mechanismGastrointestinal	Human: 2 results from 2 studies: 2 no significant change. Strongest design: Randomized controlled trial	No results	No results	No results	2
Appetite and food intakeMetabolic and weight	Human: 1 result from 1 study: 1 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	1
Body compositionMetabolic and weight	Human: 1 result from 1 study: 1 no significant change. Strongest design: Non-randomized trial	No results	No results	No results	1

Glepaglutide studies and research data

Glepaglutide identity

Targets

Sequence and structure

Sequence

Parent: Human GLP-2

Properties

Net charge by pH

Composition

3D structure

2D structure

Helical wheel

Glepaglutide results by year and outcome

What the studies measured

Glepaglutide studies on stomach and gut

Glepaglutide studies on side effects

Glepaglutide studies on liver

Glepaglutide studies on survival and serious illness

Glepaglutide studies on blood levels and clearance

Glepaglutide studies on weight and appetite

Glepaglutide studies on daily life and fitness

Glepaglutide studies on receptors and cell signals

Glepaglutide studies on heart and blood vessels

Glepaglutide studies on immune system and inflammation

Glepaglutide trials

Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS

Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial

Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome

Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)

The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome

A Phase 2 Trial Testing ZP1848 in Patients With SBS

A Bridging Trial to Compare the PK Profile When Glepaglutide is Administered Via Vial/Syringe Versus Autoinjector.

Pharmacokinetic Profile of Glepaglutide After a Single Injection in Subjects With Varying Degrees of Renal Function

Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects

Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending Dose

Papers

Studies with results

Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial.

Effect of Glepaglutide, a Long-Acting Glucagon-Like Peptide-2 Analog, on Gastrointestinal Transit Time and Motility in Patients With Short Bowel Syndrome: Findings From a Randomized Trial.

Effects of glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, on markers of liver status in patients with short bowel syndrome: findings from a randomised phase 2 trial.

Effects of glepaglutide, a long-acting glucagon-like peptide-2 analog, on intestinal morphology and perfusion in patients with short bowel syndrome: Findings from a randomized phase 2 trial.

Bile acid-farnesoid X receptor-fibroblast growth factor 19 axis in patients with short bowel syndrome: The randomized, glepaglutide phase 2 trial.

Pharmacokinetics of Glepaglutide, A Long-Acting Glucagon-Like Peptide-2 Analogue: A Study in Healthy Subjects.

Glepaglutide, a novel glucagon-like peptide-2 agonist, has anti-inflammatory and mucosal regenerative effects in an experimental model of inflammatory bowel disease in rats.

Short- versus long-term, gender and species differences in the intestinotrophic effects of long-acting glucagon-like peptide 2 analog.

Outcomes of glepaglutide on intestinal absorption and parenteral support in patients with short bowel syndrome.

Glepaglutide-Loaded Foam for the Induction of Mucosal Healing in the Treatment of Inflammatory Bowel Disease.

Investigation of the stool microbiome of short bowel syndrome patients before and after a 24-week treatment with the glucagon-like peptide 2 analog glepaglutide.

Exploring the disease burden and quality of life in patients with short bowel syndrome with intestinal failure: Insights from exit interviews in the glepaglutide EASE SBS-1 phase 3 trial.

More studies

Therapeutic Potential of GLP-2 Analogs in Gastrointestinal Disorders: Current Knowledge, Nutritional Aspects, and Future Perspectives.

Glepaglutide, a Long-Acting Glucagon-like Peptide-2 Analogue, Reduces Parenteral Support in Patients With Short Bowel Syndrome: A Phase 3 Randomized Controlled Trial.

Efficacy and safety of glucagon-like peptide 2 in patients with short bowel syndrome: a systematic review and network meta-analysis.

An updated overview of glucagon-like peptide-2 analog trophic therapy for short bowel syndrome in adults.

Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment.

Intestinal adaptation and rehabilitation in adults with short bowel syndrome.

Positive clinical outcomes associated with use of glucagon-like peptide-2 (GLP-2) analogues in patients with intestinal failure: A systematic review and meta-analysis.

Glucagon-Like Peptide-2 (GLP-2) Analogues in Patients With Short Bowel Syndrome Dependent on Parenteral Support: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Glucagon-like peptide agonists and use in short bowel syndrome - what about the side effects?

Beyond intestinal failure: Expanding therapeutic frontiers of glucagon-like peptide-2 in gastrointestinal disease.

Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome.

Differential Responses of the GLP-1 and GLP-2 Receptors to N-Terminal Modification of a Dual Agonist.

Creating Glepaglutide, the First Long-Acting GLP-2 Analogue to Enable a Ready-to-Use Injection.

Newer studies

Glepaglutide studies: 13 papers with results

Regulatory and safety

Human evidence· 21

Doses studied · 19

Data and API

Peptide

Latest changes

For developers

Related peptides

Glepaglutide results by year and outcome

Glepaglutide studies on stomach and gut

Glepaglutide studies on side effects

Glepaglutide studies on liver

Glepaglutide studies on survival and serious illness

Glepaglutide studies on blood levels and clearance